TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02388841

Intervention type: RADIATION
Intervention: Pulmonary embolism
Description: the thrombus were assessed with Computed tomographic pulmonary angiography

Intervention type: RADIATION
Intervention: Pulmonary embolism
Description: the thrombus were assessed with Computed tomographic pulmonary angiography
Study: NCT03563456

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: structured combined exercise
Description: A structured designed exercise consists of three times per week interval cardiorespiratory training of High Intensity Interval Training incorporates cycles of 1:4 interval and two times per week Resistance Exercise consists of nine-movement.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cardiorespiratory exercise
Description: Once per week continuous cardiorespiratory training of moderate intensity
Study: NCT01661920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Shorten the duration of antibiotic treatment from 7-10 days to 5 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Those antibiotic duration treatments which are not modified by their doctors.
Study: NCT03051841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-581
Description: Intravenously on Days 1, 8 of each 21-day treatment cycle.
Study: NCT00879606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-836
Description: In the first part of this study, recombinant chimeric anti-tissue factor antibody ALT-836 was administered as a single dose (0.06 mg/Kg) via intravenous infusion over 15 minutes. In the second part of this study, up to four doses (0.06 mg/Kg) of ALT-836 will be administered via intravenous infusion over 15 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the first part of this study, a single dose of Placebo was administered via intravenous infusion over 15 minutes. In the second part of this study, up to four doses of Placebo will be administered via intravenous infusion over 15 minutes.
Study: NCT05020093

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection molding
Description: preheated bilk-fill composite, co-cured universal adhesive, David Clark cavity design

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incremental packing
Description: Incremental packing of conventional composite; pre-cured universal adhesive, non-beveled cavity design
Study: NCT02833220

Intervention type: DEVICE
Intervention: Single-Pulse Transcranial Magnetic Stimulation
Description: Single-pulse Transcranial Magnetic Stimulation activates neurons within the cortex of the brain by way of electromagnetic induction. This causes a small, focused electric field to become present in the brain, which activates the neurons.
Study: NCT04311801

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography
Description: Every patient underwent OCT examination before and after surgery.
Study: NCT04156828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study: NCT01236560

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT03755479

Intervention type: DEVICE
Intervention: Hybrid Closed Loop Insulin Pump Minimed 670G
Description: Five Day Group Education on Minimed 670G
Study: NCT01969292

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colometer
Description: Real time software based image analysis tool.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Software
Description: Software that displays constant positive feedback that is unrelated to the quality measures of the actual colonoscopy.
Study: NCT02024373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 20 mg (every evening orally) for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 20 mg (every evening orally) for 8 weeks
Study: NCT04166513

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Targeted Transcranial Direct Current Stimulation
Description: High-Definition-tDCS will be delivered via a battery-driven constant direct current stimulator (Soterix) using a 4x1 montage (1 central anodal electrode and 4 cathodal electrodes) arranged in a HD-cap. The current is turned on and increased in a ramplike fashion over approximately 30 seconds until reaching a strength of no more than 2mA, with a current density equal to 0.08mA/cm2. Stimulation will be maintained no longer than 20 minutes, and stimulation will be applied to the targeted region.
Study: NCT04156828

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC
Study: NCT01236560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study: NCT04166513

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Control Transcranial Direct Current Stimulation
Description: High-Definition-tDCS will be delivered via a battery-driven constant direct current stimulator (Soterix) using a 4x1 montage (1 central anodal electrode and 4 cathodal electrodes) arranged in a HD-cap. The current is turned on and increased in a ramplike fashion over approximately 30 seconds until reaching a strength of no more than 2mA, with a current density equal to 0.08mA/cm2. Stimulation will be maintained no longer than 20 minutes, and stimulation will be applied to the active control region.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Control Transcranial Direct Current Stimulation
Description: High-Definition-tDCS will be delivered via a battery-driven constant direct current stimulator (Soterix) using a 4x1 montage (1 central anodal electrode and 4 cathodal electrodes) arranged in a HD-cap. The current is turned on and increased in a ramplike fashion over approximately 30 seconds until reaching a strength of no more than 2mA, with a current density equal to 0.08mA/cm2. Stimulation will be maintained no longer than 20 minutes, and stimulation will be applied to the active control region.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phonologic-Focused Speech Therapy
Description: Participants are asked to generate or choose from a list phonologic information about a target picture.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phonologic-Focused Speech Therapy
Description: Participants are asked to generate or choose from a list phonologic information about a target picture.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Semantic-Focused Speech Therapy
Description: Participants who have difficulty retrieving an object name are given hierarchical clues or asked questions about the objects function as a way of activating the semantic network for that object, leading to eventual retrieval of the target word.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Semantic-Focused Speech Therapy
Description: Participants who have difficulty retrieving an object name are given hierarchical clues or asked questions about the objects function as a way of activating the semantic network for that object, leading to eventual retrieval of the target word.
Study: NCT03207841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LC/HP
Description: Intervention group will receive 8 weeks of LC/HP diet. The daily LC-HP dietary intervention will include \~30% total energy as protein (1.6 g/kg per day) with a carbohydrate-to-protein ratio \<1.5 and fat intake set at \~30% of the total energy intake.
Study: NCT00853086

Intervention type: DRUG
Intervention: activated recombinant human factor VII
Description: Safety data collection in connection with the use of the drug NovoSeven® in daily clinical practice
Study: NCT01236560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study: NCT00503178

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biological imaging guided antalgic radiotherapy
Description: Biological imaging guided antalgic radiotherapy is followed.
Study: NCT04578106

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab and pertuzumab Subcutaneous Fixed-Dose Combination
Description: After 13 weeks of neoadjuvant treatment, a breast MRI will be performed. If a complete response is observed on breast MRI, patients will undergo a stereotactic-guided VAB of the marker area to obtain 12 cylinders of breast parenchyma, which is equivalent to 2 grams of tissue. If no invasive tumor cells and no in situ disease are identified in the stereotactic-guided VAB, patients will be eligible to omit loco-regional surgery.
Study: NCT01673191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid plus NSAID eye drop combination therapy
Study: NCT01337622

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No check of gastric residuals for early enteral feeding advancement
Description: Discontinuation of gastric feeding and its advancement will be based on clinical examination of the abdomen and gastric aspirates containing blood or significant vomiting.
Study: NCT02370940

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High phytate intake

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low phytate intake
Study: NCT00600028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide 50 - 100 mg by mouth daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide 50 - 100 mg by mouth daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo 50-100 mg by mouth per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo 50-100 mg by mouth per day
Study: NCT04536649

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Multimodal brain imaging-guided radiotherapy using different beams
Study: NCT01337622

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine check of gastric residuals for early enteral feeding advancement
Description: Discontinuation of gastric feeding and its advancement will be based on current practice of clinical examination of the abdomen and checking residual before every feed. Volume and color of gastric residual will be considered according to the current guideline.
Study: NCT03516240

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofreeze
Description: Following a procedure that induces muscle fatigue in the lower extremity, a topical cream will be applied over the quadriceps. The cream will be either a topical analgesic (Biofreeze) or a placebo cream. Evaluation of the movement kinematics and kinetics will be evaluated for each group.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Following a procedure that induces muscle fatigue in the lower extremity, a topical cream will be applied over the quadriceps. The cream will be either a topical analgesic (Biofreeze) or a placebo cream. Evaluation of the movement kinematics and kinetics will be evaluated for each group. Placebo cream will be blinded to both the experimenter and study participant. It will look and smell the same and will be in the same packaging.
Study: NCT01783444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Everolimus, 5 mg tablets for oral use, 10 mg (2 x 5 mg) per day (centrally supplied)
Study: NCT00532935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate (+) metformin hydrochloride
Description: sitagliptin phosphate (+) metformin hydrochloride 50/500 mg tablet bid, titrating up to sitagliptin phosphate (+) metformin hydrochloride 50/1000 mg tablet for an \~32 wk treatment period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: pioglitazone
Description: pioglitazone 30 mg tablet qd, titrating up to 45 mg qd for an \~32-wk treatment period.
Study: NCT02340845

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bromelain and Comosain
Description: Treatment of solid tumors in advanced stage of lung, breast, colon, ovary, cervix, uterus, prostatic, and liver

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bromelain and Comosain
Description: Treatment of solid tumors in advanced stage of lung, breast, colon, ovary, cervix, uterus, prostatic, and liver
Study: NCT03285789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passing tests in dyslexics with reduced eva
Description: Visual attention span : the subject see a 5 letters strings during 200 ms and he has to report it orally whatever the order Visual search : the subject has to find a target among distractors (24 or 48) in different conditions of stimuli (conjunction feature or separable feature) and different conditions of view (full view or reduced view with the moving window paradigm) Elementary visuo spatial perception: the subject passes 6 visuo spatial tests to judge his visuo spatial abilities.~All of these tests will be made during an unique visit of 1h30.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passing tests in dyslexics with reduced eva
Description: Visual attention span : the subject see a 5 letters strings during 200 ms and he has to report it orally whatever the order Visual search : the subject has to find a target among distractors (24 or 48) in different conditions of stimuli (conjunction feature or separable feature) and different conditions of view (full view or reduced view with the moving window paradigm) Elementary visuo spatial perception: the subject passes 6 visuo spatial tests to judge his visuo spatial abilities.~All of these tests will be made during an unique visit of 1h30.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passing tests in controls
Description: Visual attention span : the subject see a 5 letters strings during 200 ms and he has to report it verbally whatever the order Visual search : the subject has to find a target among distractors (24 or 48) in different conditions of stimuli (conjunction feature or separable feature) and different conditions of view (full view or reduced view with the moving window paradigm) Elementary visuo spatial perception: the subject passes 6 visuo spatial test to judge his visuo spatial abilities.~test de l'alouette : reading test during 3 minutes, we note the number of word read and the errors. We obtain lexical age.~All of these tests will be made during an unique visit of 1h30.
Study: NCT03827564

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intranasal Tear Neurostimulator (ITN) [TrueTear®]
Description: The ITN applies a small electrical current to the nasal cavities to gently activate the body's natural tear production system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intranasal Tear Neurostimulator (ITN) [TrueTear®]
Description: The ITN applies a small electrical current to the nasal cavities to gently activate the body's natural tear production system.
Study: NCT03512262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abaloparatide
Description: Abaloparatide is a synthetic peptide that is a potent and selective activator of the parathyroid hormone 1 receptor signaling pathway.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Abaloparatide-matched placebo.
Study: NCT01248325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luffa Operculate Nasal Solution 5mg/mL
Description: The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline Solution (NaCl 0,9%)
Description: The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
Study: NCT01312480

Intervention type: OTHER
Group type: OTHER
Intervention: 5A's Model
Description: The smoking cessation intervention is based on the 5A's model, which includes the following elements:~1. Ask if the patient smokes.~2. Advise every patient to quit.~3. Assess readiness to quit.~4. Assist in quitting and finding services.~5. Arrange for cessation services and follow-up.
Study: NCT02034773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: CC-220 0.3mg will be administered once daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: CC-220 1mg will be administered once daily for 28 days + 1 dose of tetanus toxoid vaccination and 1 dose of pneumococcal vaccination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: CC-220 0.3mg will be administered once daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: CC-220 1mg will be administered once daily for 7 days on 2 separate occasions, with a 7-day washout in between, for a total of 14 days of dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered once daily for up to 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: CC-220 0.3mg will be administered every 3 days for 14 days (5 total doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: CC-220 1mg (once every 7 days for 28 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: CC-220 1mg will be administered as a single dose in each of 2 study periods; once as a formulated capsule and once as two reference capsules
Study: NCT03114410

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Re:MIX, a multi-layer comprehensive teen pregnancy prevention intervention aimed at reducing pregnancy and STIs among youth ages 13-17
Description: Re:MIX is a comprehensive in-school health curriculum and teen pregnancy prevention program for adolescents covering a broad range of topics related to sexual health and youth development, including healthy relationships, communication, gender, consent, reproductive anatomy, contraception, sexual decision making, clinics, parenthood, and life planning. Re:MIX also aims to connect students and young parent educators with community resources and service linkages. The Re:MIX curriculum teaches mixed-gender groups of students in grades 8 to 10 to delay sex and use protection if they have sex. A co-facilitation team of young parent educators delivered the information with professional health educators using non-traditional approaches, such as game-based tools, technology, and storytelling. Youth received roughly nine hours and 10 minutes of group sessions during the school day over one semester (55 minutes per week for 10 weeks).
Study: NCT04456322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RT plus Nimotuzumab
Description: Nimotuzumab (200mg, once a week during radiotherapy, a total of 7 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RT plus Cisplatin
Description: concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy )
Study: NCT01618643

Intervention type: PROCEDURE
Intervention: Acetic acid chromoendoscopy
Description: Prospective observational pilot study.~We would examine patients with Barrett's epithelium that is either healthy or has suspected areas of neoplasia. We will apply acetic acid spray to areas of healthy Barrett's metaplasia and time how long it takes for the aceto whitening to disappear. We will repeat this in cases referred with SM invasive cancer, intramucosal cancer, suspected high grade dysplasia and possible low grade dysplasia. We will record how long it takes for the acetowhitening to disappear. We will biopsy these areas to confirm the diagnosis.~We will correlate the histology to the aceto-whitening time to see if there is a correlation between the degree of neoplasia and the aceto-whitening time after acetic acid dye spray.
Study: NCT02505321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Triglyceride Tolerance Test (OTTT)
Description: Participants consume a fatty drink. An intravenous catheter is inserted into the antecubital veins in one arm for intermittent sampling over the following 4 hours. The OTTT permits simple evaluation of postchallenge triglyceride levels and is acceptable to participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Triglyceride Tolerance Test (OTTT)
Description: Participants consume a fatty drink. An intravenous catheter is inserted into the antecubital veins in one arm for intermittent sampling over the following 4 hours. The OTTT permits simple evaluation of postchallenge triglyceride levels and is acceptable to participants.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal fat biopsy (optional)
Description: A sample of abdominal fat will be obtained by firstly injecting some local anaesthetic into an accessible area of the abdomen. Using a scalpel, a small incision (approx 2-3 cm) will be made to a depth of approx 15mm and two small pea-sized samples of fat will be removed. The wound will be closed with simple sutures or steristrips.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal fat biopsy (optional)
Description: A sample of abdominal fat will be obtained by firstly injecting some local anaesthetic into an accessible area of the abdomen. Using a scalpel, a small incision (approx 2-3 cm) will be made to a depth of approx 15mm and two small pea-sized samples of fat will be removed. The wound will be closed with simple sutures or steristrips.
Study: NCT04960098

Intervention type: PROCEDURE
Intervention: arthroplasty
Description: patient with hip and knee osteoarthritis underwent hip and knee arthroplasty